Teleflex Incorporated (TFX - Free Report) launched its latest line of Hudson RCI Respiratory Therapy Products at the AARC Congress 2013 held last week. New offerings from the company’s Anesthesia and Respiratory division should boost investor confidence in the stock.
TFX’ shares have demonstrated an increasing trend ever since it reported solid third-quarter financial results on Oct 30. Since then, shares have risen about 8.6% to $94.55 as of Nov 18.
Some of the new products displayed at the AARC include the Neptune Heated Humidifier with ConchaSmart Technology, Comfort Flo Humidification System, Hudson RCI ISO-Gard Mask with ClearAir Technology, and the Gibeck Humid-Flo 72-Hour Integrated Kit.
The Neptune Heater with ConchaSmart Technology has been designed to provide enhanced patient humidification as well as better workflow efficiency among clinicians. The Comfort Flo Humidification System is capable of delivering heated and humidified oxygen therapy with adjustable temperature control. The device is compliant with the AARC Clinical Practice Guidelines for Humidification during Invasive and Non-Invasive Ventilation. The Gibeck Humid-Flo 72-Hour Integrated Kit provides all kinds of humidification and ventilation assistance in a single integrated kit for a stretch of 72 hours.
Developed in collaboration with clinicians, the one-of-a-kind Hudson RCI ISO-Gard Mask is the sole solution available for “source control” of waste anesthetic gas (WAG) in a Post Anesthesia Care Unit (PACU). The unique ClearAir Technology featured with the Mask delivers oxygen to patients and at the same time, filters out their infectious counterpart in order to prevent clinicians from inhaling them. In the recent past, the company had announced the inaugural use of the ISO-Gard Mask by the Community Surgery Center North healthcare facility.
Headquartered in Limerick, PA, TFX is a leading global provider of specialty medical devices for a range of critical care and surgical procedures. Teleflex posted a 26.7% rise in adjusted earnings to $1.33 per share for the third quarter of 2013 from $1.05 earned in the comparable quarter of 2012.
With this, earnings significantly beat the Zacks Consensus Estimate of $1.14. Net revenues went up 12.4% to $413.8 million, exceeding the Zacks Consensus Estimate of $410 million.
Moreover, Teleflex upgraded its adjusted earnings per share guidance due to its continued cost reduction efforts. The company expects adjusted earnings per share in the range of $4.85 to $5.00 compared with the prior outlook of $4.70–$4.90.
We are encouraged about Teleflex’s impressive earnings beat in the third quarter and the higher EPS guidance. However, we are concerned about weaknesses in Asia and some of its product markets that induced lower revenue guidance for 2013.
Currently, TFX carries a Zacks Rank #3 (Hold). Stocks that are performing relatively well in the medical instruments industry include Cynosure, Inc. , Natus Medical Inc. (BABY - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) . While Cynosure and Natus Medical carry a Zacks Rank #1 (Strong Buy), AngioDynamics carries a Zacks Rank #2 (Buy).